IQVIA HoldingsFRA:QTS +1.14%90 OCF Yield % is 8.38 as of Jun. 30, 2026, which is 53% above its 10-year median of 5.48. GuruFocus rates FRA:QTS with a GF Score™ of 90/100 and a GF Value™ of €217.43 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, IQVIA Holdings ranks better than 78.5% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for IQVIA Holdings's OCF Yield % or its related term are showing as below:
FRA:QTS'
s OCF Yield % Range Over the Past 10 Years
Min: 3.65 Med: 5.48 Max: 11.36
Current: 8.38
During the past 13 years, the highest OCF Yield % of IQVIA Holdings was 11.36%. The lowest was 3.65%. And the median was 5.48%.
FRA:QTS's OCF Yield % is ranked better than 78.5% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.04
vs FRA:QTS: 8.38
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
IQVIA Holdings OCF Yield % Related Terms
IQVIA Holdings OCF Yield % Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:QTS vs WAT, ILMN, NTRA: OCF Yield % Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings OCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's OCF Yield % distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings (FRA:QTS) has a OCF Yield % of 8.38 as of Jun. 30, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on IQVIA Holdings and its competitors. This is 53% above median its historical median of 5.48. Over the past decade, IQVIA Holdings' OCF Yield % has ranged from 3.65 to 11.36. According to the industry distribution chart, IQVIA Holdings ranks #46 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 21.5%.
Is IQVIA Holdings' OCF Yield % too high?
IQVIA Holdings' current OCF Yield % of 8.38 is 53% above median its 10-year median of 5.48. Over the past 10 years, this metric has ranged from a low of 3.65 to a high of 11.36. The Medical Diagnostics & Research industry median OCF Yield % is 1.04. IQVIA Holdings' value of 8.38 is 705.8% above this industry median. Based on the distribution chart, IQVIA Holdings ranks #46 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IQVIA Holdings has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' OCF Yield % compare to WAT and ILMN?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #46 out of 214 companies for OCF Yield %. This places IQVIA Holdings in the top 22% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 1.04. IQVIA Holdings' value of 8.38 is 705.8% above this benchmark. Historically, IQVIA Holdings' own OCF Yield % has ranged from 3.65 to 11.36 over the past decade. While the company's 10-year median is 5.48 vs. the industry median of 1.04, IQVIA Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.04, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IQVIA Holdings's current OCF Yield % of 8.38 is 705.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on IQVIA Holdings and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IQVIA Holdings's current OCF Yield % is 8.38, which is 53% above median its own 10-year median of 5.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (FRA:QTS) is currently considered Modestly Undervalued. The stock's GF Value™ is €217.43, compared to a current price of €168.75 — trading 22.4% below its estimated fair value. The current OCF Yield % is 8.38, which is 53% above median its 10-year median of 5.48 and 705.8% above the Medical Diagnostics & Research industry median of 1.04. IQVIA Holdings' overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For IQVIA Holdings (FRA:QTS), the current OCF Yield % is 8.38 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (FRA:QTS) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of €168.75 is trading 22.4% below its estimated GF Value™ of €217.43.
GuruFocus considers IQVIA Holdings to be Modestly Undervalued.
Key valuation signals for FRA:QTS:
OCF Yield %: 8.38 (53% above median its 10-year median of 5.48)
GF Value™: €217.43 vs. price of €168.75 (22.4% below fair value)
Industry Position: 705.8% above the Medical Diagnostics & Research median (#46 of 214)
No single metric tells the full story. See the FRA:QTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
90GF Score
Get the complete analysis for FRA:QTS
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:QTS has been successfully added to your 
